-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$29.5046.04% Upside
Monopar Therapeutics Inc. Frequently Asked Questions
-
What analysts cover Monopar Therapeutics Inc.?
Monopar Therapeutics Inc. has been rated by research analysts at UBS, H.C. Wainwright in the past 90 days.